Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ATP-dependent RNA helicase DHX33 is a member of the DEAH box family of RNA helicases characterized by the Asp-Glu-Ala-His (DEAH) motif[2][4]. DHX33 functions as an essential enzyme in multiple aspects of RNA metabolism, including unwinding secondary structures in RNA to promote translation initiation, facilitating ribosome biogenesis via nucleolar organization, and sensing cytosolic double-stranded RNA to activate immune responses such as NLRP3 inflammasome formation and type I interferon production[1][2][3][4]. DHX33 is required for global protein synthesis, cell growth, and proliferation, and is induced by oncogenic signaling pathways. It is involved in both normal cellular physiology and disease, notably as a critical driver in cancer and inflammation, and represents a promising therapeutic target due to its central role in mRNA translation and cell proliferation[1][3][4][5].
Inhibition of DHX33 helicase activity impairs ribosome biogenesis and disrupts mRNA translation, leading to reduced protein synthesis and cell proliferation[1][4][5]. Activation of ferroptosis pathway (for KY386)[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ATP-dependent RNA helicase DHX33 (DHX33).